Vivos Therapeutics, Inc., headquartered in Littleton, Colorado, is a pioneering medical technology company established in 2016, formerly known as Vivos BioTechnologies, Inc. The company was founded with a transformative mission to address the underlying anatomical causes of dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. By shifting the paradigm from traditional, often palliative, symptom-management approaches toward structural, non-invasive, and non-surgical solutions, Vivos has carved out a unique niche in the dental and sleep medicine sectors. The company’s core philosophy centers on the belief that many sleep-disordered breathing issues are rooted in underdeveloped or misaligned craniofacial structures, which can be corrected through specialized, multi-disciplinary treatment protocols.
At the heart of the company’s portfolio is 'The Vivos Method,' a proprietary, non-pharmaceutical treatment modality designed to remodel the upper airway and improve breathing function. This method utilizes custom-fitted oral appliances that work in conjunction with multi-disciplinary care to address the root causes of OSA and related dentofacial issues. Beyond its flagship treatment, the company offers the VivoScore Program, an integrated screening and home sleep testing solution that provides clinicians with actionable data to diagnose and monitor patients effectively. These technological innovations represent a significant departure from traditional CPAP therapy, offering patients a more comfortable, patient-compliant, and long-term solution to chronic sleep disorders.
Vivos Therapeutics operates primarily within the United States and Canada, targeting a vast network of licensed dental professionals who serve as the primary delivery channel for its therapies. By empowering general dentists with the training, technology, and clinical support necessary to treat sleep apnea, Vivos has effectively decentralized the treatment of sleep-disordered breathing, moving it from specialized sleep clinics into the broader dental practice environment. This strategic positioning allows the company to tap into a massive, underserved patient demographic suffering from undiagnosed or poorly managed sleep apnea, thereby expanding the reach of its proprietary medical technology.
Looking toward the future, Vivos Therapeutics is focused on scaling its clinical adoption and securing further regulatory validation to solidify its market presence. The company’s strategic direction involves continuous investment in clinical research to demonstrate the long-term efficacy of its appliances, alongside efforts to integrate its solutions into mainstream medical insurance reimbursement frameworks. By fostering deeper collaborations with medical and dental practitioners and leveraging its proprietary data-driven screening tools, Vivos aims to become the standard of care for non-surgical airway management, ultimately improving the quality of life for millions of patients suffering from chronic sleep-related health conditions.
Economic Moat
Vivos Therapeutics maintains a robust competitive advantage through its proprietary, FDA-cleared 'Vivos Method' and a comprehensive intellectual property portfolio that protects its unique oral appliance technology. By creating a specialized ecosystem that integrates clinical training, diagnostic software, and proprietary hardware, the company has established high switching costs for dental practitioners who rely on the Vivos infrastructure to treat sleep-disordered breathing.